Why is the Cochlear (ASX:COH) share price tumbling 5% on Thursday?

It's a rough day on the ASX for healthcare stocks.

| More on:
Graph showing a fall in share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Cochlear is one of the worst performing ASX 200 healthcare stocks on Thursday
  • Right now, its share price is 5.2% lower, trading at $181.54
  • No news to explain the slump but some brokers are bearish on revenue growth

The Cochlear Limited (ASX: COH) share price is in the red today. In fact, its slump places it as one of the worst-performing healthcare stocks on the S&P/ASX 200 Index (ASX: XJO) on Thursday.

At the time of writing, the Cochlear share price is $181.54, 5.2% lower than its previous close.

For context, the ASX 200 is also in the red right now, having dipped 2.3% by lunchtime.

Let's take a look at what's happening with the hearing device manufacturer and distributor.

What's dragging the Cochlear share price lower today?

Cochlear's shares are weighing on the S&P/ASX 200 Health Care Index (ASX: XHJ) on Thursday.

Right now, healthcare is one of the ASX 200's worst-performing sectors, having slumped 3.8%.

Though, the title has evaded it due to the S&P/ASX 200 Information Technology Index's (ASX: XIJ) 4.86% tumble.

Amongst the ASX healthcare stocks, the Clinuvel Pharmaceuticals Limited (ASX: CUV) share price is down 5%. The Resmed CDI (ASX: RMD) and CSL Limited (ASX: CSL) share prices are both down by about 3.7%.

To make Cochlear's tumble more baffling, there's been no price-sensitive news from the company since August. Then, it released its results for the financial year 2021, inspiring the market to bid the Cochlear share price 7.4% lower.

The company isn't expected to release its results for the first half of the financial year 2022 until around 22 February.

However, The Motley Fool Australia has recently reported on multiple broker updates regarding the Cochlear share price.

For instance, Macquarie recently dropped its price target for Cochlear shares to $222.50, representing a 22% upside on its current level. Credit Suisse is bullish on the future of Cochlear, slapping a $235 price target on its shares.

Though, my Foolish colleague Tony recently reported that some experts are concerned about the company's revenue growth amid the ongoing COVID-19 pandemic.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. and Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »